Effect of berberine on Cdk9 and cyclin T1 expressions in myocardium of diabetic rats

Journal of Medical Colleges of PLA

Volumn 23, Issue 1, 2008, Pages 45-51

  Jiyin, Zhou ^a   Shiwen, Zhou ^a   Jianlin, Tang ^a   Ying, Xu ^a   Yi, Ying ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Berberine; Cdk9; Cyclin T1; Diabetes mellitus; Myocardium

Indexed keywords

BERBERINE; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; EOSIN; FENOFIBRATE; HEMATOXYLIN; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE DIET; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; FIBROSING ALVEOLITIS; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID DIET; LOW DRUG DOSE; MALE; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES;

EID: 77949443140     PISSN: 10001948     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1000-1948(08)60008-8     Document Type: Article

References (24)

1. The diabetes control and complications trial research group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14):977-986.
2. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837-853.
3. Garcia MJ, McNamara PM, Gordon T, et al. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974, 23(2):105-111.
4. Ziegler D Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev 1994, 10(4):339-383.
5. Haider B, Yeh CK, Thomas G, et al. Influence of diabetes on the myocardium and coronary arteries of rhesus monkey fed an atherogenic diet. Circ Res 1981, 49(6):1278-1288.
6. Dynlacht B Regulation of transcription by proteins that control the cell cycle. Nature 1997, 389(6647):149-152.
7. Zhu Y, Pe'ery T, Peng J, et al. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev 1997, 11(20):2622-2632.
8. Mancebo H, Lee G, Flygare J, et al. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev 1997, 11(20):2633-2644.
9. Inzucchi SE Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002, 287(3):360-372.
10. Kim YY, Kang HJ, Ko SK, et al. Sopungsungiwon (SP) prevents the onset of hyperglycemia and hyperlipidemia in Zucker diabetic fatty rats. Arch Pharm Res 2002, 25(6):923-931.
11. Leng SH, Lu FE, Xu LJ Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin 2004, 25(4):496-502.
12. Srinivasan K, Viswanad B, Asrat L, et al. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005, 52(4):313-320.
13. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001, 103(22):2668-2673.
14. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321(7258):412-419.
15. Tomlinson KC, Gardiner SM, Hebden RA, et al. Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol Rev 1992, 44(1):103-150.
16. Zhang XM, Shen F, Xv ZY, et al. Expression changes of thrombospondin-1 and neuropeptide Y in myocardium of STZ-induced rats. Int J Cardiol 2005, 105(2):192-197.
17. Xie W, Xing D, Sun H, et al. The effects of Ananas comosus L. leaves on diabeticdyslipidemic rats induced by alloxan and a high-fat/high-cholesterol diet. Am J Chin Med 2005, 33(1):95-105.
18. Khan MA, St Peter JV, Xue JL A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002, 25(4):708-711.
19. Watanabe K, Fujii H, Takahashi T, et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-ependent cardiac toxicity. J Biol Chem 2000, 275(29):22293-22299.
20. Tenenbaum A, Motro M, Fisman EZ Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005, 4:14.
21. Huang C, Zhang Y, Gong Z, et al. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPAR gamma pathway. Biochem Biophys Res Commun 2006, 348(2):571-578.
22. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004, 10(12):1344-1351.
23. Brusq JM, Ancellin N, Grondin P, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 2006, 47(6):1281-1288.
24. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55(8):2256-2264.